Former FDA Commissioner Scott Gottlieb, M.D. is returning to global venture capital firm New Enterprise Associates (NEA) as a Special Partner on the firm’s healthcare investment team. Dr. Gottlieb was a Venture Partner at NEA from 2007 to 2017 before being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019.
Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access. He is focused on advancing public health to improve medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
During his tenure at the FDA, Dr. Gottlieb helped oversee a modernization of the FDA’s new drug and medical device review programs and historic reorganization of the agency’s field operations; and led the passage and implementation of significant new legislation, including new bills to address the opioid crisis and expand the agency’s user fee programs. He promoted new platforms for advancing medical product safety and presided over a 20 percent increase in the agency’s budget over two years.
With more than $20 billion in cumulative committed capital since the firm’s first fund closed in 1978, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 225 portfolio company IPOs and more than 375 acquisitions.
“Throughout his prior 10-year tenure at NEA, Scott’s broad expertise was a tremendous asset for our healthcare practice and portfolio companies,” said David Mott, General Partner and Head of Healthcare Investing at NEA. “We are proud of his contributions to advancing innovation and increasing the quality of patient care as head of the FDA, and we’re thrilled to have him rejoin NEA, this time as a full-time investing partner. Scott will be based in our Chevy Chase, Maryland office and will be an active investor across the full spectrum of our healthcare activities, with a particular emphasis on biopharma and healthcare services. Scott is an invaluable resource for our entrepreneurs and our investing team as we work together to advance new products and services to better serve patients.”
